Blueprint Medicines Corp
BPMCDelisted Jul 18, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001597264
Blueprint Medicines Corp was delisted on Jul 18, 2025; its insiders filed their last Form 4 on Jul 21, 2025; 356 institutions reported holding it in 13F filings for Q2 2025, worth $8.65B in total; Soros Fund Management was the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding Blueprint Medicines Corp changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 240 | 2 | 223 | −15 |
| Shares | 63.0M | 51.5K | 62.6M | −344.7K (−0.5%) |
| Value | $4.15B | $3.39M | $2.74B | −$1.40B (−33.9%) |
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (31)
Institutions that held Blueprint Medicines Corp at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (46)
Institutions that held Blueprint Medicines Corp at the end of Q3 2022 and filed for Q4 2022 without it.
Not filed for Q4 2022 yet (2)
Institutions that held Blueprint Medicines Corp at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Eaton Vance Management | 51,484 | $3.39M |
| American Portfolios Advisors | 10 | $659 |